Biomarkers: ApoB vs LDL — Why the Better Cardiovascular Marker Isn't What Your Doctor Usually Checks

Two people can have identical LDL cholesterol — and one of them can have twice the cardiovascular risk of the other. ApoB is the reason.

LDL cholesterol has been the standard measure of cardiovascular risk for decades. It's on every lipid panel, familiar to every doctor, and the target of every statin prescription. It's also, in an important sense, the wrong number to focus on.

The Problem with LDL

LDL-C (LDL cholesterol) measures the total mass of cholesterol carried by LDL particles. But it's not cholesterol mass that causes arterial plaque — it's the number of particles. A small, dense LDL particle carrying less cholesterol is more dangerous than a larger, less dense particle carrying more, because the small, dense particle more easily penetrates the arterial wall. Two people with the same LDL-C can have very different particle counts.

This is the discordance problem. In clinical practice, LDL-C and particle count are usually aligned — but in a meaningful minority of patients, particularly those with high triglycerides, metabolic syndrome, or insulin resistance, they diverge substantially. In these cases, LDL-C consistently underestimates cardiovascular risk.

What ApoB Actually Measures

Apolipoprotein B is the structural protein that sits on the surface of every atherogenic (plaque-forming) lipoprotein: LDL, VLDL, IDL, and Lp(a). Critically, each particle has exactly one ApoB molecule. So measuring ApoB gives a direct count of the total number of atherogenic particles in your blood.

This is simpler, more direct, and more informative than any cholesterol measurement. It doesn't matter how much cholesterol each particle is carrying. What matters is how many particles there are — because each one is a potential seed for arterial plaque.

Research has confirmed this consistently. A 2016 CARDIA study tracked young adults for 25 years and found that high ApoB with normal LDL-C predicted future coronary artery calcification, while high LDL-C with normal ApoB did not. The particle count was the causal factor. Cholesterol mass was not.

What the Research Says About Target Levels

ApoB less than 90 mg/dL is considered desirable by most lipidology guidelines. The European Society of Cardiology and the National Lipid Association recommend ApoB below 100 mg/dL as a general target, with lower thresholds for higher-risk individuals. Longevity-focused physicians like Peter Attia advocate for levels closer to 60 mg/dL — the 5th percentile of the population — as an aspirational target for primary prevention.

In the app, we use 0.9 g/L (90 mg/dL) as our longevity-optimal target and 1.3 g/L (130 mg/dL) as the clinical upper threshold. This is a reasonable, evidence-grounded position that doesn't require medication for most people — it's achievable through diet and lifestyle for the majority of individuals with moderately elevated ApoB.

How to Lower ApoB

ApoB responds to the same interventions that lower LDL-C — but more completely, because it captures the full atherogenic particle burden:

Reduce insulin resistance: High triglycerides drive VLDL production, which increases total ApoB. Reducing refined carbohydrates, intermittent fasting, and improving insulin sensitivity are the most powerful dietary levers.

Reduce saturated fat: Replacing saturated fat with unsaturated fat consistently reduces ApoB in most people. This does not mean a low-fat diet — it means replacing butter, processed meat, and coconut oil with olive oil, avocados, and fatty fish.

Exercise: Aerobic training improves LDL particle size and lowers ApoB independently of diet.

If lifestyle isn't enough: Statins lower ApoB significantly. If dietary changes don't move it to the target range within 3–6 months, this is worth a conversation with your doctor.

The 100 Great Years perspective

Cardiovascular disease is the leading cause of death globally — and it is largely preventable, when caught early enough and managed with the right metrics. ApoB is the right metric. The tragedy of cardiovascular disease is its slow, invisible development over decades: the process that causes a heart attack at 60 often began at 35. Tracking ApoB rather than — or alongside — LDL gives you a more accurate view of that process, earlier. 100 Great Years exists for the decades before something goes wrong. ApoB is one of the clearest signals available for what is happening in those decades.

See what your biomarkers reveal

Get your free Health and Wealth scores in 5 minutes.

This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before making decisions about your health.